ERA
The Endometrial Receptivity Array (ERA) is a molecular tool used for evaluate the endometrial receptivity for infertility treatments. Which can reduce the number of failed cycles, eliminate cost, and save valuable patient time.
The endometrium is a highly dynamic tissue with the capacity to undergo physiological changes in response to steroid hormones in order to synchronize its receptivity to the implanted blastocyst during the “window of implantation” (WOI) between days 20 and 21 of the menstrual cycle.
Until now, the only method to evaluate the endometrium was by ultrasound; however, traditional dating by Noyes criteria have demonstrated not to be related with the fertility status and are affected by the subjectivity of the observer. For that, it was important in reproductive medicine, to objectively identify and diagnose the endometrial receptivity status during the WOI. Now it is possible with the Endometrial Receptivity Array (ERA).
This unique, innovative and objective procedure improves endometrium related evaluations and diagnosis. It defines the transcriptomic signature of human endometrial receptivity. The ERA is a genomic tool composed of a customized microarray and a bioinformatic predictor for endometrial dating and to detect pathologies of an endometrial origin. The ERA includes 238 selected genes, which have been shown to be differentially expressed in the transition from the pre-receptive status to receptive status. The transcriptomic signature was defined by 134 genes. The endometrial dating attempts to classify an LH+7 endometrium in transcriptomic terms with a specificity and sensitivity of 0.8857 and 0.99758, respectively. These results show the diagnostic power of ERA for endometrial dating.
This diagnostic tool is now being used clinically in reproductive medicine and gynecology due to the transcriptomic signature is a potential endometrial receptivity biomarkers cluster. This is the first time that a molecular tool, based on functional genomics can be used clinically in reproductive medicine to evaluate the endometrium, for that, ERA provides a new perspective to the clinician.
Available for clinical use, it will increase implantation rates, consequentially reducing the number of failed cycles, eliminate cost and save valuable time for our patients.
For more information about the information or company described above, please provide the following details, as well as a brief comment or question. Thank you for your interest. Fields marked with * are obligatory.
The Valencian region’s push in biotechnology has created very fertile ground for outside investment in the numerous spin-offs and start ups. One of the objectives for Bioval is to identify the innovative ideas and business opportunities based in Biotechnology to provide alternatives to traditional investment options. Grow with Biotechnolgy. More information.
The biotechnology sector in the Valencian Region is already composed of a diverse mix of companies, ranging from multinational sector leaders, to innovative start up companies beginning to make their mark. The diversity of these companies is further expounded by the broad range of biotech projects.
